Haleon plc (NYSE:HLN) Shares Acquired by Millennium Management LLC

Millennium Management LLC increased its position in Haleon plc (NYSE:HLN - Free Report) by 82.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 528,891 shares of the company's stock after purchasing an additional 239,019 shares during the quarter. Millennium Management LLC's holdings in Haleon were worth $5,046,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of HLN. Wellington Management Group LLP grew its stake in Haleon by 67.5% in the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after purchasing an additional 6,175,835 shares in the last quarter. Raymond James Financial Inc. bought a new position in Haleon in the fourth quarter worth approximately $42,193,000. FMR LLC grew its stake in Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after purchasing an additional 3,909,545 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Haleon in the fourth quarter worth approximately $39,628,000. Finally, Northern Trust Corp grew its stake in Haleon by 27.7% in the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after purchasing an additional 1,172,931 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Price Performance

Shares of NYSE:HLN traded up $0.03 during trading on Friday, reaching $11.36. 24,804,983 shares of the company's stock traded hands, compared to its average volume of 8,488,277. Haleon plc has a fifty-two week low of $8.25 and a fifty-two week high of $11.40. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $51.17 billion, a PE ratio of 33.41, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a 50-day simple moving average of $10.40 and a 200-day simple moving average of $9.97.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. As a group, analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a research note on Friday, May 9th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday. Finally, Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Haleon currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.